Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
NVE Corporation Q4 FY2026 Earnings Call - Non-Defense Sales Surge 34% as Defense Revenue Dips and Capacity Doubles
NVE Corporation delivered a sharp rebound in its non-defense business during Q4 FY2026, with product sales jumping 34% year-over-year to offset a steep 79% decline in defense revenue. The company repo...
- Non-defense product sales surged 34% year-over-year in Q4, driving a 27% increase in net income to $4.9 million or $1.02 per diluted share.
- Total revenue rose 5% to $7.65 million, with product sales up 6% offset by a 19% decline in contract R&D revenue.
- Defense product sales plummeted 79% year-over-year, but management expects a significant recovery in defense sales for fiscal 2027.
- +7 more takeaways
Kratos Defense & Security Solutions Q1 2026 Earnings Call - Record Backlog and Margin Expansion Signals Defense Industrial Base Rebuild
Kratos Defense & Security Solutions delivered a strong start to 2026, with Q1 revenue of $371 million significantly beating estimates and organic growth accelerating across unmanned systems, turbine t...
- Q1 2026 revenue reached $371 million, exceeding the high end of the $335–345 million estimate and reflecting 15.8% organic growth.
- The company reported a record backlog of $2 billion and an opportunity pipeline exceeding $14 billion, with a 1.6:1 overall book-to-bill ratio and a 3:1 ratio specifically in satellite communications.
- Unmanned Systems revenue grew 30.9% organically, driven by Valkyrie program activity and tactical drone awards, while Turbine Technologies saw 20.3% organic growth.
- +7 more takeaways
Tarsus Pharmaceuticals Q1 2026 Earnings Call - XDEMVY Sales Surge 85% as ECPs Expand Treatment Beyond Classic Demodex Cases
Tarsus Pharmaceuticals delivered another quarter of exceptional momentum with XDEMVY net product sales jumping 85% year-over-year to $145.4 million. The growth is no longer just about launch velocity....
- XDEMVY net product sales reached $145.4 million in Q1 2026, an 85% year-over-year increase, driven by deeper prescribing and a widening patient funnel.
- Eye care physicians are expanding treatment beyond classic Demodex blepharitis cases, now screening and treating patients with keratoconus, chalazia, and preoperative cataract conditions.
- Retreatment rates have climbed to the mid-teens and are expected to stabilize at approximately 20% of total prescriptions at steady state.
- +7 more takeaways
Herbalife Ltd. Q1 2026 Earnings Call - Personalized Nutrition Push Drives Strong India Growth and Record Sales
Herbalife delivered a robust start to 2026, with first quarter net sales rising 7.8% year-over-year to $1.3 billion and adjusted EBITDA hitting $176 million, both exceeding guidance. The results were ...
- Net sales reached $1.3 billion, up 7.8% year-over-year and 5.4% on a constant currency basis, marking the third consecutive quarter of growth and beating the high end of guidance.
- India delivered record quarterly net sales of $275 million, driven by a 32% year-over-year increase, fueled by strong demand following a September 2025 GST rate reduction.
- Adjusted EBITDA came in at $176 million, above the $175 million high end of guidance, with an adjusted EBITDA margin of 13.3%.
- +7 more takeaways
electroCore Q1 2026 Earnings Call - Revenue Surges 43% as VA Penetration and Consumer Efficiency Drive Operating Leverage
electroCore delivered its strongest quarter to date, with revenue jumping 43% year-over-year to $9.6 million. Gross margins expanded to 87%, and adjusted EBITDA losses narrowed by 24%, signaling clear...
- Record Q1 revenue of $9.6 million, up 43% year-over-year, driven by 48% growth in prescription device sales within the VA system.
- Gross margin expanded 200 basis points to 87%, with adjusted EBITDA loss narrowing 24% to $2.3 million, demonstrating clear operating leverage.
- Quell Fibromyalgia surpassed $1 million in quarterly revenue for the first time, adding to cumulative VA sales of $2.5 million since acquisition.
- +7 more takeaways
Axon Enterprise Q1 2026 Earnings Call - AI Era Plan Drives 140% Bookings Surge and Dedrone Scales Beyond Expectations
Axon Enterprise delivered a record first quarter, with revenue climbing 34% year-over-year to $807 million and software and services growing 35% to $355 million. The standout driver was the Axon AI Er...
- Revenue reached $807 million, up 34% year-over-year, marking the ninth consecutive quarter of growth above 30%
- Software and services revenue grew 35% to $355 million, with AI product revenue surging more than 700% year-over-year
- Future contracted bookings hit a record $14.3 billion, up 44% year-over-year, driven by broad-based demand across all markets
- +7 more takeaways
Alpha Teknova Q1 2026 Earnings Call - Clinical Solutions Surge and 2027 Growth Ambitions
Alpha Teknova delivered a solid Q1 2026 with revenue up 13% year-over-year to $11.2 million, driven by an 85% surge in Clinical Solutions revenue. The company is shifting from cash conservation to str...
- Q1 2026 revenue grew 13% year-over-year to $11.2 million, the first Q1 in nearly three years to exceed $11 million.
- Clinical Solutions revenue surged 85% to $2.1 million, driven by broader customer base and higher average order values.
- Lab Essentials revenue stabilized at $8.4 million, up 3%, with higher revenue per customer offsetting a decline in active customer count.
- +7 more takeaways
Amplitude Q1 2026 Earnings Call - Aggressive AI Pivot and Statsig Partnership Drive Platform Expansion
Amplitude is racing to redefine its category by transforming into an AI-native company. The Q1 2026 results show solid top-line growth with revenue of $94.5 million, up 17% year-over-year, and strong ...
- Q1 2026 revenue reached $94.5 million, representing a 17% year-over-year increase, while annual recurring revenue (ARR) grew to $374 million, up 17% year-over-year and $9 million sequentially.
- Amplitude announced a strategic partnership with Statsig, taking on the brand, customer base, and technology for experimentation and feature management, aiming to combine it with Amplitude’s analytics platform.
- Dollar-based net retention improved to 106% from 105% in the prior quarter, driven by strong cross-sell expansions and deeper multi-product adoption across the customer base.
- +7 more takeaways
Hamilton Beach Brands Q1 2026 Earnings Call - Margin Surge Offsets Sales Softness
Hamilton Beach Brands delivered a quarter defined by a stark divergence between top-line pressure and bottom-line resilience. Revenue fell 8.6% to $122 million as consumer spending weakened and March ...
- Revenue declined 8.6% to $122 million, missing expectations due to softer March consumer demand and elevated fuel costs weighing on discretionary spending.
- Gross margin expanded by 510 basis points to 29.7%, driven by pricing actions, favorable product mix, and a one-time 190 basis point benefit from tariff inventory positioning.
- Operating profit more than doubled to $5 million, resulting in net income of $3.5 million or $0.26 per diluted share, significantly beating prior year guidance.
- +7 more takeaways
Realty Income Q1 2026 Earnings Call - Private Capital Ecosystem Drives Guideline Hikes and Yield Expansion
Realty Income delivered a strong Q1 2026, reporting AFFO per share of $1.13, up 6.6% year-over-year, and deployed $2.8 billion in investments at a 7.1% initial weighted average cash yield. The company...
- AFFO per share reached $1.13, a 6.6% year-over-year increase, supporting a $0.025 raise in full-year guidance midpoint.
- Investment volume totaled $2.8 billion at a 7.1% initial weighted average cash yield, with a balanced geographic split between North America and Europe.
- Full-year investment volume guidance was raised to $9.5 billion, reflecting a robust pipeline and expanded capital deployment capacity.
- +7 more takeaways